MindWalk (HYFT) Competitors

MindWalk logo
$0.68 -0.12 (-14.45%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$0.69 +0.00 (+0.23%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

HYFT vs. QTRX, CDXS, MXCT, SEER, and CSBR

Should you buy MindWalk stock or one of its competitors? MindWalk's main competitors and comparable companies include Quanterix (QTRX), Codexis (CDXS), MaxCyte (MXCT), Seer (SEER), and Champions Oncology (CSBR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does MindWalk compare to Quanterix?

MindWalk (NASDAQ:HYFT) and Quanterix (NASDAQ:QTRX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, media sentiment, analyst recommendations and institutional ownership.

In the previous week, MindWalk and MindWalk both had 4 articles in the media. Quanterix's average media sentiment score of 0.23 beat MindWalk's score of 0.00 indicating that Quanterix is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MindWalk
0 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Quanterix
0 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

MindWalk has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market. Comparatively, Quanterix has a beta of 1.06, meaning that its share price is 6% more volatile than the broader market.

Quanterix has a net margin of -75.05% compared to MindWalk's net margin of -105.11%. Quanterix's return on equity of -30.49% beat MindWalk's return on equity.

Company Net Margins Return on Equity Return on Assets
MindWalk-105.11% -133.26% -77.78%
Quanterix -75.05%-30.49%-22.44%

6.7% of MindWalk shares are owned by institutional investors. Comparatively, 86.5% of Quanterix shares are owned by institutional investors. 6.8% of MindWalk shares are owned by company insiders. Comparatively, 1.5% of Quanterix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

MindWalk currently has a consensus price target of $5.00, indicating a potential upside of 630.57%. Quanterix has a consensus price target of $3.50, indicating a potential upside of 78.57%. Given MindWalk's stronger consensus rating and higher probable upside, research analysts clearly believe MindWalk is more favorable than Quanterix.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MindWalk
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.60
Quanterix
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67

MindWalk has higher earnings, but lower revenue than Quanterix. MindWalk is trading at a lower price-to-earnings ratio than Quanterix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MindWalk$11.24M2.90-$10.11M-$0.26N/A
Quanterix$138.90M0.67-$107.15M-$2.36N/A

Summary

MindWalk beats Quanterix on 8 of the 15 factors compared between the two stocks.

How does MindWalk compare to Codexis?

MindWalk (NASDAQ:HYFT) and Codexis (NASDAQ:CDXS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk and valuation.

In the previous week, Codexis had 7 more articles in the media than MindWalk. MarketBeat recorded 11 mentions for Codexis and 4 mentions for MindWalk. Codexis' average media sentiment score of 0.33 beat MindWalk's score of 0.00 indicating that Codexis is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MindWalk
0 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Codexis
3 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

MindWalk has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market. Comparatively, Codexis has a beta of 2.38, meaning that its share price is 138% more volatile than the broader market.

Codexis has a net margin of -21.77% compared to MindWalk's net margin of -105.11%. Codexis' return on equity of -43.24% beat MindWalk's return on equity.

Company Net Margins Return on Equity Return on Assets
MindWalk-105.11% -133.26% -77.78%
Codexis -21.77%-43.24%-14.21%

6.7% of MindWalk shares are held by institutional investors. Comparatively, 78.5% of Codexis shares are held by institutional investors. 6.8% of MindWalk shares are held by insiders. Comparatively, 3.5% of Codexis shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

MindWalk currently has a consensus target price of $5.00, suggesting a potential upside of 630.57%. Codexis has a consensus target price of $6.00, suggesting a potential upside of 506.06%. Given MindWalk's stronger consensus rating and higher probable upside, research analysts clearly believe MindWalk is more favorable than Codexis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MindWalk
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.60
Codexis
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

MindWalk has higher earnings, but lower revenue than Codexis. Codexis is trading at a lower price-to-earnings ratio than MindWalk, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MindWalk$11.24M2.90-$10.11M-$0.26N/A
Codexis$70.39M1.54-$43.97M-$0.20N/A

Summary

Codexis beats MindWalk on 10 of the 16 factors compared between the two stocks.

How does MindWalk compare to MaxCyte?

MaxCyte (NASDAQ:MXCT) and MindWalk (NASDAQ:HYFT) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and media sentiment.

MindWalk has lower revenue, but higher earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than MindWalk, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MaxCyte$33.03M4.30-$44.63M-$0.26N/A
MindWalk$11.24M2.90-$10.11M-$0.26N/A

MaxCyte presently has a consensus price target of $4.50, suggesting a potential upside of 227.27%. MindWalk has a consensus price target of $5.00, suggesting a potential upside of 630.57%. Given MindWalk's stronger consensus rating and higher probable upside, analysts clearly believe MindWalk is more favorable than MaxCyte.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MaxCyte
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
MindWalk
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.60

In the previous week, MindWalk had 1 more articles in the media than MaxCyte. MarketBeat recorded 4 mentions for MindWalk and 3 mentions for MaxCyte. MaxCyte's average media sentiment score of 1.92 beat MindWalk's score of 0.00 indicating that MaxCyte is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MaxCyte
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
MindWalk
0 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

MaxCyte has a beta of 1.49, meaning that its share price is 49% more volatile than the broader market. Comparatively, MindWalk has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market.

MaxCyte has a net margin of -81.40% compared to MindWalk's net margin of -105.11%. MaxCyte's return on equity of -15.05% beat MindWalk's return on equity.

Company Net Margins Return on Equity Return on Assets
MaxCyte-81.40% -15.05% -12.79%
MindWalk -105.11%-133.26%-77.78%

68.8% of MaxCyte shares are held by institutional investors. Comparatively, 6.7% of MindWalk shares are held by institutional investors. 4.1% of MaxCyte shares are held by insiders. Comparatively, 6.8% of MindWalk shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

MaxCyte beats MindWalk on 8 of the 15 factors compared between the two stocks.

How does MindWalk compare to Seer?

MindWalk (NASDAQ:HYFT) and Seer (NASDAQ:SEER) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, media sentiment, valuation and risk.

6.7% of MindWalk shares are held by institutional investors. Comparatively, 75.2% of Seer shares are held by institutional investors. 6.8% of MindWalk shares are held by insiders. Comparatively, 11.3% of Seer shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

MindWalk has a beta of 0.79, suggesting that its share price is 21% less volatile than the broader market. Comparatively, Seer has a beta of 1.49, suggesting that its share price is 49% more volatile than the broader market.

MindWalk has a net margin of -105.11% compared to Seer's net margin of -450.86%. Seer's return on equity of -27.03% beat MindWalk's return on equity.

Company Net Margins Return on Equity Return on Assets
MindWalk-105.11% -133.26% -77.78%
Seer -450.86%-27.03%-23.80%

MindWalk has higher earnings, but lower revenue than Seer. MindWalk is trading at a lower price-to-earnings ratio than Seer, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MindWalk$11.24M2.90-$10.11M-$0.26N/A
Seer$16.58M4.54-$73.60M-$1.15N/A

MindWalk presently has a consensus target price of $5.00, suggesting a potential upside of 630.57%. Seer has a consensus target price of $4.00, suggesting a potential upside of 194.12%. Given MindWalk's higher possible upside, research analysts clearly believe MindWalk is more favorable than Seer.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MindWalk
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.60
Seer
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
2 Strong Buy rating(s)
3.00

In the previous week, MindWalk had 3 more articles in the media than Seer. MarketBeat recorded 4 mentions for MindWalk and 1 mentions for Seer. MindWalk's average media sentiment score of 0.00 beat Seer's score of -1.00 indicating that MindWalk is being referred to more favorably in the media.

Company Overall Sentiment
MindWalk Neutral
Seer Negative

Summary

Seer beats MindWalk on 9 of the 16 factors compared between the two stocks.

How does MindWalk compare to Champions Oncology?

MindWalk (NASDAQ:HYFT) and Champions Oncology (NASDAQ:CSBR) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, valuation, analyst recommendations, profitability, earnings and risk.

In the previous week, MindWalk had 4 more articles in the media than Champions Oncology. MarketBeat recorded 4 mentions for MindWalk and 0 mentions for Champions Oncology. MindWalk's average media sentiment score of 0.00 equaled Champions Oncology'saverage media sentiment score.

Company Overall Sentiment
MindWalk Neutral
Champions Oncology Neutral

Champions Oncology has higher revenue and earnings than MindWalk. Champions Oncology is trading at a lower price-to-earnings ratio than MindWalk, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MindWalk$11.24M2.90-$10.11M-$0.26N/A
Champions Oncology$59.42M1.01-$1.17M-$0.08N/A

Champions Oncology has a net margin of -1.82% compared to MindWalk's net margin of -105.11%. Champions Oncology's return on equity of -25.77% beat MindWalk's return on equity.

Company Net Margins Return on Equity Return on Assets
MindWalk-105.11% -133.26% -77.78%
Champions Oncology -1.82%-25.77%-3.71%

MindWalk has a beta of 0.79, suggesting that its share price is 21% less volatile than the broader market. Comparatively, Champions Oncology has a beta of 0.48, suggesting that its share price is 52% less volatile than the broader market.

6.7% of MindWalk shares are held by institutional investors. Comparatively, 41.3% of Champions Oncology shares are held by institutional investors. 6.8% of MindWalk shares are held by insiders. Comparatively, 46.3% of Champions Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

MindWalk currently has a consensus price target of $5.00, indicating a potential upside of 630.57%. Given MindWalk's stronger consensus rating and higher possible upside, equities analysts plainly believe MindWalk is more favorable than Champions Oncology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MindWalk
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.60
Champions Oncology
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Champions Oncology beats MindWalk on 8 of the 15 factors compared between the two stocks.

Get MindWalk News Delivered to You Automatically

Sign up to receive the latest news and ratings for HYFT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HYFT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HYFT vs. The Competition

MetricMindWalkLife Sciences Tools & Services IndustryHealthcare SectorNASDAQ Exchange
Market Cap$44.62M$10.69B$7.78B$11.72B
Dividend YieldN/A1.46%2.47%4.72%
P/E RatioN/A48.3432.1926.74
Price / Sales2.908.468.105.42
Price / CashN/A26.5521.0121.90
Price / Book3.804.194.263.50
Net Income-$10.11M$56.66B$3.50B$394.12M
1 Month Performance-46.11%-7.92%-10.48%-12.15%
1 Year PerformanceN/A11.01%-4.61%-11.41%

MindWalk Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HYFT
MindWalk
1.4801 of 5 stars
$0.68
-14.5%
$5.00
+630.6%
N/A$44.62M$11.24MN/A77
QTRX
Quanterix
1.6025 of 5 stars
$3.01
+5.3%
$3.50
+16.2%
-66.8%$142.68M$138.90MN/A450
CDXS
Codexis
3.0973 of 5 stars
$1.11
+15.3%
$6.50
+488.2%
-36.9%$121.01M$70.39MN/A146
MXCT
MaxCyte
4.2895 of 5 stars
$1.15
-3.8%
$4.50
+293.0%
-15.6%$118.22M$33.03MN/A91
SEER
Seer
3.1353 of 5 stars
$1.54
-3.1%
$4.00
+159.7%
-29.9%$85.27M$16.58MN/A124

Related Companies and Tools


This page (NASDAQ:HYFT) was last updated on 11/21/2026 by MarketBeat.com Staff.
From Our Partners